TherapyX Inc.
http://therapyxinc.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TherapyX Inc.
Finance Watch: VC Mega-Rounds Make A Comeback In March
Private Company Edition: After just seven venture capital rounds of $100m or more in January and February, five have been announced already in March, including a $200m series A round for Cargo Therapeutics, Chroma Medicine’s $135m series B financing and $112m for Noema’s series B.
Public/Private Partnerships Keep Gonorrhea Drug Development Alive
Only two new antibiotics are in Phase III trials for gonorrhea: Entasis’ zoliflodacin, in collaboration with the Global Antibiotic R&D Partnership, and GlaxoSmithKline’s gepotidacin in partnership with the US Biomedical Advanced R&D Authority.
Early Results For Therapyx/Intravacc's Vaccine May Herald Progress In Gonorrhea Prevention
Therapyx and Intravacc are optimizing a candidate gonorrhea vaccine following promising results in primates and the granting of a three-year SBIR award by the US NIAID.
Appointments: Bayer, Mustang, Modus, GammaDelta, Poxel, Metrion and Renova.
This week's roundup includes CEO appointments by various companies including Mustang Bio, GammaDelta and Modus Therapeutics and other high-level appointments by Bayer, Renova, Metrion and Poxel.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice